Pharma stocks rally on May 14 as Cipla, Zydus Lifesciences, Strides Pharma and Wockhardt lead gains

Pharmaceutical stocks opened strongly on May 14, 2026, with broad-based buying visible across large-cap, mid-cap and small-cap counters during the early morning session.

The BSE Healthcare index rose 1.27% to 46,735.35, outperforming the broader market. As of around 9:26 AM, the Nifty 50 was up 0.67% at 23,569.45, while the S&P BSE Sensex gained 0.55% to 75,019.03.

Among pharma stocks, Cipla emerged as the biggest gainer. The stock surged 7.15% on the BSE to Rs 1,422 and gained 6.11% on the NSE to Rs 1,408.70.

Zydus Lifesciences also traded higher, rising 3.74% on the BSE to Rs 974.05 and 4.01% on the NSE to Rs 976.90. Strides Pharma Science gained 2.20% on the BSE to Rs 1,171.45, while Wockhardt rose 2.12% to Rs 1,601.95.

Orchid Pharma also traded with gains in the range of 2.13% to 2.34%. Other notable gainers included IPCA Laboratories, Glenmark Pharma, Aurobindo Pharma, Lupin, Mankind Pharma, Ajanta Pharma, Alembic Pharma, Torrent Pharma, Natco Pharma and Aarti Drugs.

Several other pharma and healthcare names also traded in positive territory. Biocon, Divis Laboratories, J.B. Chemicals, Sun Pharma and Sudeep Pharma posted modest gains ranging from 0.5% to 1.7%.

On the losing side, Dr. Reddy’s Laboratories and Panacea Biotech were among the few stocks trading marginally lower in the early session.

Overall, the pharma sector started the day on a strong note, with the BSE Healthcare index outperforming the benchmark indices. Cipla, Zydus Lifesciences, Strides Pharma, Wockhardt and Orchid Pharma led the early gains, while only a few counters traded in the red.

Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Prices and percentage changes are based on early trade data and may change during the session. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Fingo is not liable for any losses arising from the use of this information.